HDL and Reverse Cholesterol Transport
A more clean and in higher definition animation to explain the functions of HDL-C and the Reverse Cholesterol Transport mechanism. As shown in recent studies (AIM-HIGH & HPS2-THRIVE), HDL-C increase alone cannot be associated to cardiovascular benefits, especially when LDL-C is very low. HDL-C remains a marker to assess cardiovascular risk (the higher the HDL-C the less the cardiovascular risk) but not a Risk Factor: meaning that raising HDL-C is not proven to provide benefit. Complexicity of HDL-C functions does not allow simplifications such as to determine CV Benefit just from HDL-C consentration (eg: mg/dL) modifications. Number and size of HDL-C particles, concentration of Apo-A1, and the actual Reverse Cholesterol Efflux need to be considered. More trials are underway to finally conclude on this matter. LDL-C remains the primary treatment target (recent guidelines also mention non-HDL and Apo-B as secondary targets).